HIV/AIDS News

SAN FRANCISCO — Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic Infections.

The White House withdrew the nomination of David Weldon, MD, to be CDC director on Thursday morning, just hours before he was to appear before a Senate committee.

SAN FRANCISCO — Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that could transform the landscape of HIV prevention.

SAN FRANCISCO — During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV survivor, addressed conference attendees and discussed her experiences of living with HIV.

SAN FRANCISCO — HIV incidence in sub-Saharan Africa has declined substantially, according to both UNAIDS estimates and empirical data pulled from decades of studies, researchers found.

Home-based HIV counseling and relationship building improved HIV testing, diagnoses and viral suppression among pregnant couples during a trial in Kenya, researchers reported.

Senators questioned Jay Bhattacharya, MD, PhD, about proposed NIH cuts to biomedical research, the safety of vaccines, and government transparency during his nomination hearing Wednesday to be the next director of the NIH.

A recent survey conducted by the HIV Medicine Association identified barriers to implementation of long-acting injectables for HIV prevention which included the need for prior authorization and funding issues.

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV infection and set a date of June 19 to decide on its approval, Gilead announced Tuesday.